Thrombin
drugOn this page
Also known as Coagulation factor iiaHuman thrombinThrombin (human)Thrombin bovineThrombin humanThrombin human plasma-derivedThrombin topical humanThrombin, topical (human)ThrombineTrombina
Summary
Thrombin (CHEMBL2108110) is an approved unknown (ATC B02BD30); indicated across 11 conditions including lung disorder and neoplasm.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Unknown
- ATC class: B02BD30 (+1 more)
- Indications: 11 conditions
- Clinical trials: 10
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2108110 |
| Name | Thrombin |
| Type | Unknown |
| Max phase | 4 |
| ATC | B02BD30, B02BC06 |
Also known as: Coagulation factor iia, Human thrombin, Thrombin, Thrombin (human), Thrombin bovine, Thrombin human, Thrombin human plasma-derived, Thrombin topical human, Thrombin, topical (human), Thrombine, Trombina, THROMBIN
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
11 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| lung disorder | 3 | MONDO:0005275 | EFO:0003818 |
| neoplasm | 3 | MONDO:0005070 | EFO:0000616 |
| ischemia reperfusion injury | 2 | MONDO:0005203 | EFO:0002687 |
| staphylococcus aureus infection | 2 | MONDO:0005545 | EFO:0005681 |
| burn | 2 | MONDO:0043519 | EFO:0009516 |
| injury | 2 | MONDO:0021178 | EFO:0000546 |
| hemophilia A | 2 | MONDO:0010602 | MONDO:0010602 |
4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 10.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 4 |
| PHASE4 | 2 |
| Not specified | 2 |
| PHASE2 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00242437 | PHASE4 | COMPLETED | Hemostatic Matrix in Endoscopic Sinus Surgery |
| NCT00440401 | PHASE4 | COMPLETED | TachoSil® Versus Standard Haemostatic Treatment of Haemorrhage in Cardiovascular Surgery (TC-023-IM) |
| NCT00196534 | PHASE3 | COMPLETED | A Study to Compare Human Thrombin Against Bovine Thrombin in Its Ability to Stop Bleeding After Surgery |
| NCT00245336 | PHASE3 | COMPLETED | Study of Recombinant Human Thrombin for Bleeding During Surgery |
| NCT00759681 | PHASE3 | COMPLETED | ArterX Surgical Sealant, A Randomized Prospective Multicenter Trial |
| NCT01717612 | PHASE3 | UNKNOWN | A Prospective, Randomized Trial of Histoacryl Injection Versus Thrombin in the Control of Acute Gastric Variceal Bleeding |
| NCT02014402 | PHASE2 | COMPLETED | Safety and Efficacy of Topical Thrombin (Human) Grifols as an Adjunct to Hemostasis During Surgery |
| NCT00618358 | PHASE1 | TERMINATED | Vascular Sealant Study |
| NCT05713734 | Not specified | RECRUITING | Bleeding of Unknown Cause: a Swiss Case-control Study |
| NCT00439309 | Not specified | TERMINATED | Study to Evaluate Safety & Effectiveness of Vascular Sealant System |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: lung disorder, neoplasm